4. Executive Summary Incidence of CML 0.002% 20% Resistance/Intolerance to 1stline treatment Pluto® is indicated for this unmet need Resistant/ Intolerant
5. Executive Summary Market Size 20% of 1600pt Market Distribution: 1 competitor TargetedMarket Share 65% (Year 1) Targeted Sales ~3.5-4 millions (Year 1) Expected Market growth rate/year 2% Total sales/ First 5 years ~20 millions
6. Executive Summary Concentrated Strategy How ? Positioning the Product Promotional Activity (Personal selling, Advertising, Public Relations) Phase IV or clinical trials Monitoring ? Sales Tracking Market Share Tracking
21. Strategy Implementation: Costs Abroad Meetings (Mirac®) 1 District Manager RTDs 3 Medical Representatives Brochures and Gifts First two years Prescriptions Monitoring and Evaluation
Find Egypt’s current total population, find total CML patients number per year “internet”Check if Mirac is the standard current therapy
We need a logo for our drug, Pluto Pluto is indicated to meet this unmet need of our resistant and intolerant patients.
Market size : 20% of 1600 CML pt. / year.Market distribution: Pluto and Disatinib.Targeted Market share: 65% Sales of year 1 : plz add ya alia Expected market growth/year: 2% Total sales for the 1st 5 years: Plz add ya alia
How can we achieve this Target? Concentrated strategy.Positioning our Brand. (vs. Competitor Disatinib) . Promotional activityPersonal selling. Advertising. Public Relations.How will we monitor our Plan ?Phase 4 clincal trials for the 1st 2 years.Sales tracking Market share tracking.
We will successfully introduce our priceless innovation to control, prevent and cure one of the most challenging diseases to achieve high reduction in morbidity and mortalities and provide a radical turning point in the quality of life. In addition to establishing devoted exponentially increasing shareholder return consequently rewarding all contributers in Novartis”You can say that we have two directions, the major one is “Patient satisfaction” which is achieved thru slide 8 and increasing the company’s market share or whatever which achieved via slide 9
We will successfully introduce our priceless innovation to control, prevent and cure one of the most challenging diseases to achieve high reduction in morbidity and mortalities and provide a radical turning point in the quality of life. In addition to establishing devoted exponentially increasing shareholder return consequently rewarding all contributers in Novartis”
I don’t know what you have in mind for the rationale, bas we can make it a separate slide or write an indicative text about it
Building confidence in the drug efficacy
Sales were calculated on a yearly basis, with an expected market share increment of 2-3% and taking the increase in patients’ number relative to the Egyptian Population in consideration
So every time you hear the name pluto now, we hope you won’t remember the planet,nor the dog, we hope you were remember Pluto, the resort to which CML patients adsolve.
